Uncomplicated group | Complicated group | |||||
Levo. | Azithro. | 95% CI¶ | Levo. | Amox./clav. | 95% CI¶ | |
Pathogen category | ||||||
Gram-positive aerobic pathogens | 20/22 (90.9) | 12/15 (80.0) | −37.8–16.0 | 21/24 (87.5) | 14/19 (73.7) | −40.3–12.6 |
Gram-negative aerobic pathogens | 76/81 (93.8) | 88/105 (83.8) | −19.4–0.6 | 75/93 (80.6) | 88/106 (83.0) | −8.9–13.7 |
Total by pathogen | 96/103 (93.2) | 100/120 (83.3) | −18.6– −1.1 | 96/117 (82.1) | 102/125 (81.6) | −10.6–9.7 |
Total by patient+ | 75/80 (93.8) | 72/87 (82.8) | −21.2– −0.8 | 70/86 (81.4) | 71/89 (79.8) | −13.9–10.7 |
Pathogen | ||||||
Enterobacter cloacae | 1/1 (100.0) | 3/5 (60.0) | 0/0 (0.0) | 0/0 (0.0) | ||
Haemophilus influenzae | 26/27 (96.3) | 21/24 (87.5) | −25.9–8.3 | 25/30§ (83.3) | 20/20 (100.0) | 0.8–32.5 |
Haemophilus parainfluenzae | 18/20 (90.0) | 20/23 (87.0) | −24.6–18.5 | 18/20 (90.0) | 15/18 (83.3) | −31.1–17.8 |
Klebsiella pneumoniae | 2/2 (100.0) | 5/6 (83.3) | 1/2 (50.0) | 4/5 (80.0) | ||
Moraxella catarrhalis | 14/14 (100.0) | 18/20 (90.0) | −26.7–6.7 | 10/12 (83.3) | 16/19 (84.2) | −30.0–31.8 |
Pseudomonas aeruginosa | 3/3 (100.0) | 4/6 (66.7) | 3/5 (60.0) | 4/5 (80.0) | ||
Staphylococcus aureus | 7/7 (100.0) | 0/2 (0.0) | 4/5 (80.0) | 3/5 (60.0) | ||
Streptococcus pneumoniae | 11/12 (91.7) | 10/11 (90.9) | −28.4–26.9 | 16/18 (88.9) | 10/13 (76.9) | −42.9–19.0 |
Data are presented as n/N (%), unless otherwise stated. Levo.: levofloxacin; azithro.: azithromycin; CI: confidence interval; amox.: amoxicillin; clav.: clavulanate. #: eradication plus presumed eradication; ¶: two-sided 95% CI around the difference of comparator minus levofloxacin; +: eradication of all pathogens identified at study entry for a patient; §: one patient was inappropriately assessed as a failure by the investigator, even though all of the patient's baseline symptoms were resolved and H. influenzae had been eradicated.